Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-29

FDA Approved: DELSTRIGO — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for DELSTRIGO, a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate, from Merck Sha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DELSTRIGO (DORAVIRINE, LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE)

Snippet

SUPPL AP for DELSTRIGO (DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE)